Summary Data Dashboard

Learn and interact with the data by viewing, filtering, or exporting the charts below.

The following dashboard of publicly-available, aggregate data provides a quick overview of available AMP PD data. This dashboard represents core data characteristics associated with: participant demographics, distributions for cohort and participant data, and collected data types (clinical, whole genome, and transcriptomics).

Refine Data by

Data as of:

Total Case vs Control Participants

  1. Total PD Case Participants - quantity is derived from the Enrollment assessment and [study_arm] variable and includes the following values: PD; Genetic Registry PD; Prodromal; and SWEDD
  2. Total Control Participants - quantity is derived from the Enrollment assessment and [study_arm] variable and includes the following values: Genetic Registry Unaffected; Healthy Control; and Disease Control

Biological Sex Within Cohort

Participant Race Distribution

  1. White/Caucasian category consolidates race values for (1) White and (2) Caucasian (e.g., British Isles, Germany, Peninsular Spain, Latin America, France, Italy, Ireland, Sweden, etc.)
  2. Black/African-American category consolidates race values for (1) Black or African American and (2) American - Black (i.e., people of African descent whose area of origin is within the Americas: e.g., Canada, Caribbean, Brazil, US, etc.) 

Participant Age Distribution

Whole Genome Sequencing in Blood

115 participants were added to the AMP PD database after the final joint genotyping analysis was run and their mutation status is therefore unknown.

RNA Sequencing in Blood

  1. GBA: N370S (rs76763715); T369M (rs75548401); E326K (rs2230288)
  2. LRRK2: G2019S (rs34637584); R1441G_T (rs33939927); R1441G_G (rs33939927)
  3. SNCA: A53T (rs104893877); G51D (rs431905511); E46K (rs104893875); A30P (rs104893878)

Most Common Participant Diagnoses

  1. Other category consolidates diagnoses with 10 or less participants. The following diagnoses fall into this category:
    • Alzheimer's Disease
    • Corticobasal Degeneration
    • Fahr's Sydrome
    • Hemiparkinson/Hemiatrophy Syndrome
    • Juvenile Autosomal Recessive Parkinsonism
    • Neuroleptic-Induced Parkinsonism
    • Olivopontocerebellar Atrophy
    • Parkinsonism
    • Possible Alzheimer's Disease
    • Psychogenic Illness
    • Unknown
    • Vascular Parkinsonism
  2. Prodromal motor PD - represents at least one motor symptom to meet eligibility for enrollment in PPMI as PD subject
  3. Prodromal non-motor PD - represents at least one non-motor symptom and no motor symptoms
  4. Participant diagnosis is listed as it was designated by the cohort.  “Idiopathic PD” and “Parkinson’s Disease” are the diagnoses used by the PPMI and PDBP cohorts respectively and are not intended to indicate whether the participant has a known mutation or not.  Similarly, all participants with a neurological disorder in the LBD cohort were designated as “LBD”, without the more specific designations of “PDD” or “DLB”; other cohorts used the more specific designations.

Proteomics in Plasma and CSF